Australians considering prescription treatment for weight management can now ask about Wegovy in tablet form. The Therapeutic Goods Administration approved the tablets on 2 November 2026 and registered them on 3 November. Novo Nordisk said the tablets would be available on private prescription from Friday, 20 November, although pharmacy stock may vary.
The TGA-approved tablets contain semaglutide and come in four strengths: 1.5mg, 4mg, 9mg and 25mg. For chronic weight management, they are approved for adults alongside a reduced-energy diet and increased physical activity. The approved weight-management indication covers adults with a body mass index (BMI) of at least 30, or a BMI of at least 27 and below 30 with a weight-related health condition. The tablets are also approved to reduce the risk of major cardiovascular events in certain adults with established cardiovascular disease, a BMI of at least 27 and no established type 1 or type 2 diabetes.
Novo Nordisk’s recommended monthly prices are $260 for 1.5mg, $270 for 4mg, $280 for 9mg and $395 for 25mg. Pharmacy prices may differ. Wegovy is not subsidised through the Pharmaceutical Benefits Scheme (PBS) for weight management, so patients using it for that purpose should expect to pay the full pharmacy price.
For patients, the tablet offers an oral alternative to the weekly Wegovy injection, but it is taken once every day and has strict timing instructions. Anyone considering it should discuss eligibility, risks and other medicines with a prescriber. A prescription and TGA approval do not guarantee that a particular pharmacy has every strength in stock.
The Australian product information says to take the tablet after fasting for at least eight hours. Swallow it whole with up to 120 millilitres of water; do not split, crush or chew it. Wait at least 30 minutes before eating, drinking or taking other oral medicines. The product information says a shorter wait may reduce semaglutide absorption.
The tablet is approved for specified adult weight-management and cardiovascular-risk indications, and its price depends on dose and pharmacy. Patients should confirm the current price and stock with a pharmacy and discuss treatment with their prescriber. Follow the product information and advice from a health professional when taking Wegovy.